New cancer clinical trial: LATENT: Lytic Activation To Enhance Neoantigen-directed Therapy A Combination of Anti-viral and Immune Therapy for the Treatment of Cancers Associated With Chronic Viral Infections

Published on: November 30, 2017 at 10:00AM
Condition:   Cancer That is Associated With a Chronic Viral Infection
Interventions:   Drug: Valproic Acid;   Biological: Avelumab
Sponsors:   AHS Cancer Control Alberta;   EMD Serono / Merck
Not yet recruiting
http://ift.tt/2AHEWsQ